Gadoteridol

This classification denotes a gadolinium-chelate with the molecular formula C17H29GdN4O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0199MV609F, chemically known as 1,4,7,10-tetraazacyclododecan-1,4,7-triacetic acid, 10-(2-hydroxypropyl)-, gadolinium complex but more generally known as gadoteridol, which bears U.S. National Institutes of Health Compound Identifier 60714. The European Medicines Agency schedules Gadoteridol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07866MIG. The term GADOTERIDOL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 5, No. 3 1991, List 31). The World Health Organization schedules gadoteridol in its Anatomical Therapeutic Chemical (ATC) Classification. GADOTERIDOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: [GD].OC(CN1CCN(CCN(CCN(CC1)CC(=O)O)CC(=O)O)CC(=O)O)C. Most nations schedule Gadoteridol under HS 28469000.